Cargando…

Disutilities Associated with Intravenous Iron Infusions: Results from a Time Trade-off Survey and Diminishing Marginal Utility Model for Treatment Attributes in China

PURPOSE: Treatment process attributes can affect health state utilities associated with therapy. For intravenous iron, used to treat iron deficiency and iron deficiency anemia, research into process attributes is still lacking. This study estimated utilities associated with process attributes for in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Shanlian, Wu, Depei, Wu, Jing, Zhang, Yabing, Bøgelund, Mette, Pöhlmann, Johannes, Pollock, Richard F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543423/
https://www.ncbi.nlm.nih.gov/pubmed/37789883
http://dx.doi.org/10.2147/PROM.S400389
_version_ 1785114297148375040
author Hu, Shanlian
Wu, Depei
Wu, Jing
Zhang, Yabing
Bøgelund, Mette
Pöhlmann, Johannes
Pollock, Richard F
author_facet Hu, Shanlian
Wu, Depei
Wu, Jing
Zhang, Yabing
Bøgelund, Mette
Pöhlmann, Johannes
Pollock, Richard F
author_sort Hu, Shanlian
collection PubMed
description PURPOSE: Treatment process attributes can affect health state utilities associated with therapy. For intravenous iron, used to treat iron deficiency and iron deficiency anemia, research into process attributes is still lacking. This study estimated utilities associated with process attributes for intravenous iron infusions. METHODS: An online survey including seven health state vignettes and time trade-off tasks was administered to participants, who were not patients living with iron deficiency or iron deficiency anemia, from a Chinese online panel. Vignettes used an identical description of iron deficiency and iron deficiency anemia but differed in the annual number of infusions, infusion duration, and infusion-associated risk of hypophosphatemic osteomalacia. Disutilities and their rate of change as the number of infusions increased were examined using a power model. RESULTS: The survey was completed by 1091 participants. The highest utilities were observed for one annual infusion of 15–30 minutes or 30–60 minutes, without risk of hypophosphatemic osteomalacia (0.754 and 0.746, respectively). In comparison, more infusions and infusions with a risk of hypophosphatemic osteomalacia were associated with lower utilities. Utility continued to decrease, but at a diminishing rate, as the annual number of infusions increased, with utility decrements of 0.006 and 0.002, respectively, when going from zero to one and from four to five infusions per year. All marginal disutilities were small (values <0.01). CONCLUSION: This study suggested that treatment attributes of intravenous iron infusions affect health state utilities. Using intravenous iron formulations that allow for fewer and shorter infusions without the risk of hypophosphatemic osteomalacia can reduce the number of visits required and increase patients’ quality of life.
format Online
Article
Text
id pubmed-10543423
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-105434232023-10-03 Disutilities Associated with Intravenous Iron Infusions: Results from a Time Trade-off Survey and Diminishing Marginal Utility Model for Treatment Attributes in China Hu, Shanlian Wu, Depei Wu, Jing Zhang, Yabing Bøgelund, Mette Pöhlmann, Johannes Pollock, Richard F Patient Relat Outcome Meas Original Research PURPOSE: Treatment process attributes can affect health state utilities associated with therapy. For intravenous iron, used to treat iron deficiency and iron deficiency anemia, research into process attributes is still lacking. This study estimated utilities associated with process attributes for intravenous iron infusions. METHODS: An online survey including seven health state vignettes and time trade-off tasks was administered to participants, who were not patients living with iron deficiency or iron deficiency anemia, from a Chinese online panel. Vignettes used an identical description of iron deficiency and iron deficiency anemia but differed in the annual number of infusions, infusion duration, and infusion-associated risk of hypophosphatemic osteomalacia. Disutilities and their rate of change as the number of infusions increased were examined using a power model. RESULTS: The survey was completed by 1091 participants. The highest utilities were observed for one annual infusion of 15–30 minutes or 30–60 minutes, without risk of hypophosphatemic osteomalacia (0.754 and 0.746, respectively). In comparison, more infusions and infusions with a risk of hypophosphatemic osteomalacia were associated with lower utilities. Utility continued to decrease, but at a diminishing rate, as the annual number of infusions increased, with utility decrements of 0.006 and 0.002, respectively, when going from zero to one and from four to five infusions per year. All marginal disutilities were small (values <0.01). CONCLUSION: This study suggested that treatment attributes of intravenous iron infusions affect health state utilities. Using intravenous iron formulations that allow for fewer and shorter infusions without the risk of hypophosphatemic osteomalacia can reduce the number of visits required and increase patients’ quality of life. Dove 2023-09-26 /pmc/articles/PMC10543423/ /pubmed/37789883 http://dx.doi.org/10.2147/PROM.S400389 Text en © 2023 Hu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Hu, Shanlian
Wu, Depei
Wu, Jing
Zhang, Yabing
Bøgelund, Mette
Pöhlmann, Johannes
Pollock, Richard F
Disutilities Associated with Intravenous Iron Infusions: Results from a Time Trade-off Survey and Diminishing Marginal Utility Model for Treatment Attributes in China
title Disutilities Associated with Intravenous Iron Infusions: Results from a Time Trade-off Survey and Diminishing Marginal Utility Model for Treatment Attributes in China
title_full Disutilities Associated with Intravenous Iron Infusions: Results from a Time Trade-off Survey and Diminishing Marginal Utility Model for Treatment Attributes in China
title_fullStr Disutilities Associated with Intravenous Iron Infusions: Results from a Time Trade-off Survey and Diminishing Marginal Utility Model for Treatment Attributes in China
title_full_unstemmed Disutilities Associated with Intravenous Iron Infusions: Results from a Time Trade-off Survey and Diminishing Marginal Utility Model for Treatment Attributes in China
title_short Disutilities Associated with Intravenous Iron Infusions: Results from a Time Trade-off Survey and Diminishing Marginal Utility Model for Treatment Attributes in China
title_sort disutilities associated with intravenous iron infusions: results from a time trade-off survey and diminishing marginal utility model for treatment attributes in china
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543423/
https://www.ncbi.nlm.nih.gov/pubmed/37789883
http://dx.doi.org/10.2147/PROM.S400389
work_keys_str_mv AT hushanlian disutilitiesassociatedwithintravenousironinfusionsresultsfromatimetradeoffsurveyanddiminishingmarginalutilitymodelfortreatmentattributesinchina
AT wudepei disutilitiesassociatedwithintravenousironinfusionsresultsfromatimetradeoffsurveyanddiminishingmarginalutilitymodelfortreatmentattributesinchina
AT wujing disutilitiesassociatedwithintravenousironinfusionsresultsfromatimetradeoffsurveyanddiminishingmarginalutilitymodelfortreatmentattributesinchina
AT zhangyabing disutilitiesassociatedwithintravenousironinfusionsresultsfromatimetradeoffsurveyanddiminishingmarginalutilitymodelfortreatmentattributesinchina
AT bøgelundmette disutilitiesassociatedwithintravenousironinfusionsresultsfromatimetradeoffsurveyanddiminishingmarginalutilitymodelfortreatmentattributesinchina
AT pohlmannjohannes disutilitiesassociatedwithintravenousironinfusionsresultsfromatimetradeoffsurveyanddiminishingmarginalutilitymodelfortreatmentattributesinchina
AT pollockrichardf disutilitiesassociatedwithintravenousironinfusionsresultsfromatimetradeoffsurveyanddiminishingmarginalutilitymodelfortreatmentattributesinchina